Arvinas Inc (NAS:ARVN)

$ 25.98 1.5 (6.13%) Market Cap: 1.79 Bil Enterprise Value: 665.07 Mil PE Ratio: 0 PB Ratio: 3.05 GF Score: 72/100

Q3 2024 Arvinas Inc Earnings Call Transcript
Oct 30, 2024

$27.66 (+0.58%)

Earnings
Arvinas Inc to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program Call Transcript
Dec 06, 2023
Arvinas Inc To Host ESMO Data Presentation Call Transcript
Oct 22, 2023
Arvinas Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Sep 28, 2023
Arvinas Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2023
Arvinas Inc at Goldman Sachs Healthcare Conference Transcript
Jun 12, 2023
Arvinas Inc at Jefferies Healthcare Conference Transcript
Jun 08, 2023
Arvinas Inc at Bank of America Global Healthcare Conference Transcript
May 09, 2023
Arvinas Inc at Stifel Targeted Oncology Days (Virtual) Transcript
Apr 26, 2023
Arvinas Inc at Citi Virtual Oncology Leadership Summit Transcript
Feb 23, 2023
Arvinas, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-11-2023 01:30 PM Transcript
Jan 11, 2023
Arvinas Inc SABCS Event Transcript
Nov 22, 2022
Arvinas Inc at Bank of America Precision Oncology Conference Transcript
Oct 03, 2022
Arvinas Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2022
Arvinas Inc at Citi BioPharma Conference Transcript
Sep 08, 2022
Arvinas Inc at Bank of America Healthcare Conference Transcript
May 10, 2022
Arvinas Inc at Cowen Health Care Conference (Virtual) Transcript
Mar 07, 2022
Arvinas Inc to Discuss the Phase 1 Dose Escalation Data and Interim Data from the Phase 2 ARDENT Trial Transcript
Feb 17, 2022
Arvinas Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript
Feb 10, 2022
Arvinas Inc ARV-471 Program Update Call Transcript
Dec 10, 2021
Arvinas Inc and Pfizer Inc Announce ARV-471 Collaboration- Conference Call Transcript
Jul 22, 2021
Arvinas Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 10, 2021
Arvinas Inc at UBS Global Healthcare Virtual Conference Transcript
May 25, 2021
Arvinas Inc ASCO Data Conference Call Transcript
May 29, 2020
Arvinas Inc Conference Call Transcript
Oct 23, 2019

Arvinas, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-11-2023 01:30 PM Transcript

Jan 11, 2023 / 09:30PM GMT

Release Date Price: $30.34 (-3.71%)

Transcript

Lut Ming Cheng

JPMorgan Chase & Co, Research Division - Research Analyst

Good afternoon, everyone. Thanks for joining us for another session at the 41st JPMorgan conference. I'm Brian Cheng. I'm one of the senior biotech analysts here. Presenting next is Arvinas. I will introduce the management team from Arvinas, and then we'll follow this presentation with a Q&A session. I'll turn the stage over to Arvinas.

John G. Houston

Arvinas, Inc. - CEO, President & Director

Thank you very much. Hello. My name's John Houston, I'm the CEO of Arvinas. It's a great pleasure to be here today to talk about the company, our platform and our pipeline. Before I start, I'll show you this because I'll be making forward-looking statements and some of those may come to pass and some may not.

So Arvinas was founded in 2013. Professor Craig Crews of (Trades,

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.